U.S. health advisersare backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness.
FILE - Doses of the anti-viral drug Paxlovid are displayed in New York, on Monday, Aug. 1, 2022. The COVID-19 medication won another vote of confidence from U.S. health advisors on Thursday, March 16, 2023, clearing the way for its full regulatory approval after being used by millions of Americans under emergency use. – Pfizer’s COVID-19 pill Paxlovid won another vote of confidence from U.S.
A panel of outside experts voted 16-1 that Paxlovid remains a safe and effective treatment for high-risk adults with COVID-19 who are more likely to face hospitalization and death due to the virus. The FDA said using Paxlovid in high-risk patients could prevent 1,500 COVID-19 deaths and 13,000 hospitalizations per week.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
COVID-19 pill Paxlovid moves closer to full FDA approvalU.S. health advisersare backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness
Lire la suite »
COVID-19 pill Paxlovid moves closer to full FDA approvalPfizer’s COVID-19 pill Paxlovid won another vote of confidence from U.S. health advisers, clearing the way for its full approval by the FDA. The medication has been used by millions of Americans since it was granted emergency use authorization in 2021.
Lire la suite »
COVID-19 pill Paxlovid moves closer to full FDA approvalU.S. health advisors are backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness.
Lire la suite »
FDA: Paxlovid not associated with COVID reboundPaxlovid isn't associated with COVID rebound, in which patients test positive or have symptoms days after a course of the drug is completed, Food and Drug Administration staff said Tuesday.
Lire la suite »
No clear association between Paxlovid and COVID-19 rebound, FDA saysAn FDA analysis did not find a clear association between the COVID-19 antiviral drug Paxlovid and illness rebound, the FDA said in a new report.
Lire la suite »
Paxlovid not linked to COVID rebound, FDA saysClinical trial data has concluded that there is no clear association with a COVID-19 rebound.
Lire la suite »